- Home
- IVA vs ITRG Comparison
IVA vs ITRG Comparison
Compare IVA & ITRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- ITRG
- Stock Information
- Founded
- IVA 2011
- ITRG 1997
- Country
- IVA France
- ITRG Canada
- Employees
- IVA N/A
- ITRG N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- ITRG Precious Metals
- Sector
- IVA Health Care
- ITRG Basic Materials
- Exchange
- IVA Nasdaq
- ITRG Nasdaq
- Market Cap
- IVA 162.8M
- ITRG N/A
- IPO Year
- IVA 2020
- ITRG N/A
- Fundamental
- Price
- IVA $2.94
- ITRG $1.24
- Analyst Decision
- IVA Strong Buy
- ITRG Strong Buy
- Analyst Count
- IVA 4
- ITRG 1
- Target Price
- IVA $13.25
- ITRG $2.75
- AVG Volume (30 Days)
- IVA 8.1K
- ITRG 488.2K
- Earning Date
- IVA 03-26-2025
- ITRG 03-26-2025
- Dividend Yield
- IVA N/A
- ITRG N/A
- EPS Growth
- IVA N/A
- ITRG N/A
- EPS
- IVA N/A
- ITRG N/A
- Revenue
- IVA $15,243,814.00
- ITRG $30,350,000.00
- Revenue This Year
- IVA $18.05
- ITRG $490.21
- Revenue Next Year
- IVA $46.74
- ITRG $37.03
- P/E Ratio
- IVA N/A
- ITRG N/A
- Revenue Growth
- IVA N/A
- ITRG N/A
- 52 Week Low
- IVA $1.53
- ITRG $0.71
- 52 Week High
- IVA $3.98
- ITRG $1.38
- Technical
- Relative Strength Index (RSI)
- IVA 53.75
- ITRG 53.74
- Support Level
- IVA $2.70
- ITRG $1.18
- Resistance Level
- IVA $3.10
- ITRG $1.38
- Average True Range (ATR)
- IVA 0.18
- ITRG 0.09
- MACD
- IVA -0.02
- ITRG -0.00
- Stochastic Oscillator
- IVA 62.50
- ITRG 53.33
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.